==== Front
J Oncol
J Oncol
JO
Journal of Oncology
1687-8450 1687-8469 Hindawi 

10.1155/2020/7406146
Corrigendum
Corrigendum to “Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease”
Zhang Guangzhi 
1

2
 Bashiri Kiandokht 
1
 Kneteman Mark 
1
 Cave Kevan 
1
 Hong Youngkee 
1
 Mackey John R. 
3
 Alter Harvey J. 
4
 https://orcid.org/0000-0002-0470-9522Mason Andrew L. andrew.mason@ualberta.ca
1

5
 
1Center of Excellence for Gastrointestinal Inflammation and Immunity Research, Division of Gastroenterology, University of Alberta, Edmonton AB T6G 2E1, Canada

2National Microbiology Laboratory, Winnipeg MB R3E 3M4, Canada

3Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

4Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892, USA

5Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB T6G 2E1, Canada
2020 
3 12 2020 
3 12 2020 
2020 74061466 11 2020 6 11 2020 Copyright © 2020 Guangzhi Zhang et al.2020This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Alberta Cancer FoundationAlberta InnovatesCanadian Institutes of Health ResearchCanadian Liver Foundation
==== Body
In the article titled “Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease” [1], a sentence in Section 2.2 was incorrect. The sentence “A serum panel of breast cancer patients (n = 98) and age/sex-matched controls (n = 102) was obtained from the Alberta Tomorrow Project, a longitudinal study tracking 55,000 adults in Alberta” should be corrected to “A serum panel of breast cancer patients (n = 98) and age/sex-matched controls (n = 102) was obtained from the breast cancer outpatient clinic Cross Cancer Institute.” The authors also wish to acknowledge an additional funding body. The modified Acknowledgments section is as follows.

Acknowledgments
We thank the Alberta Cancer Foundation, Alberta Innovates Health Solutions, Canadian Institutes for Health Research, and Canadian Liver Foundation for supporting this project as well as Michael Houghton and Michael Sakalian for their assistance. We thank the Canadian Breast Cancer Foundation for supporting this study.
==== Refs
1 Zhang G.  KiandokhtBashiri M. K.  Kevan Cave    Seroprevalence of human betaretrovirus surface protein antibodies in patients with breast cancer and liver disease Journal of Oncology  2020 2020 9 8958192 10.1155/2020/8958192